1. In Vivo
  2. >>Global Vision

Trends in Japanese Alliances

As consolidation pressures wrack the Japanese pharmaceutical industry some retrenchment in Japanese inlicensing has followed. We examine recent trends in Japanese licensing.

As consolidation pressures wrack the Japanese pharmaceutical industry some retrenchment in Japanese inlicensing has followed. (See "Roche/Chugai Blaze a Trail...But Will Anyone Follow?" Also see "Roche/Chugai Blaze a Trail...But Will Anyone Follow?" - In Vivo, 1 January, 2002. and "Merck/Banyu: A Harbinger of More Western-Japanese Deals?" IN VIVO, January 2002 and February 2003 Also see "Merck/Banyu: A Harbinger of More Western-Japanese Deals?" - In Vivo, 1 February, 2003..)

Japanese players have always been far more interested in early-stage deals, with half to two thirds of all their deals...

More from Global Vision

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By David Wild

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.